Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
No Longer Available NCT05503550

Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma

Conditions: Relapsed or Refractory Multiple Myeloma

Ages: 18 Years – N/A
Sponsor: Janssen Research & Development, LLC

Summary

The purpose of this pre-approval access program is to provide talquetamab for the treatment of participants with relapsed or refractory multiple myeloma.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05503550). StuddyBuddy aggregates publicly available trial information.